| Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES | |||||||||
Unrealized loss on trading securities | |||||||||
- | - | - | - | -401 | 401 | - | - | - | - |
Net loss | |||||||||
- | - | - | - | - | - | - | - | 13,125 | - |
Net income | |||||||||
36,901 | 8,785 | -3,749 | -35,754 | - | - | - | - | - | - |
Loss from continuing operations | |||||||||
- | - | - | - | -8,852 | -603 | -6,267 | -9,902 | - | -23,564 |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||||||||
Deferred income taxes | |||||||||
-25,205 | - | - | - | - | - | - | - | - | - |
Receipt of Mesoblast common stock | |||||||||
- | 10,000 | - | - | - | - | - | - | - | - |
Provision for excess and obsolete inventory | |||||||||
1,529 | 525 | - | - | - | - | - | - | - | - |
Settlement of SEC and shareholder actions, net of insurance | |||||||||
- | - | - | 15,212 | - | - | - | - | - | - |
Loss (gain) on disposal of fixed assets | |||||||||
- | - | -44 | 106 | - | - | - | - | - | - |
Realized loss on investments | |||||||||
-219 | -2,028 | -8 | -2,502 | - | - | - | - | - | - |
Loss on disposal of fixed assets | |||||||||
-74 | -123 | - | - | - | - | - | - | - | - |
Depreciation | |||||||||
873 | 688 | 993 | 1,035 | - | - | - | - | - | - |
Depreciation | |||||||||
- | - | - | - | 940 | 587 | 552 | 577 | 755 | 665 |
Stock-based compensation expense | |||||||||
277 | 99 | -341 | 2,814 | 2,929 | 583 | 492 | 894 | 1,684 | 2,456 |
Provision for bad debts | |||||||||
- | - | - | - | 1,628 | 80 | 22 | 3 | 0 | - |
Deferred tax benefit | |||||||||
- | - | - | - | - | - | - | - | -3,170 | - |
Non cash expense-extension of expiration date of warrant to related party | |||||||||
- | - | - | - | - | - | - | 1,740 | - | - |
Changes in operating assets and liabilities: | |||||||||
Settlement of shareholder and regulatory actions | |||||||||
-18,500 | -1,500 | - | - | - | - | - | - | - | - |
Receipt of insurance proceeds regarding the settlement of shareholder actions | |||||||||
-4,788 | - | - | - | - | - | - | - | - | - |
Accounts receivables, net | |||||||||
-3,584 | 2,805 | 4,449 | 5,426 | 7,542 | 4,685 | 2,185 | 523 | 790 | -55,149 |
Inventory, net | |||||||||
-135 | 437 | 1,789 | -247 | 7,895 | 456 | 642 | 257 | 510 | - |
Prepaid expenses and other assets | |||||||||
2,117 | 1,641 | -782 | -4,095 | 2,832 | -88 | 293 | -266 | -212 | -1,112 |
Accounts payable, accrued expenses, and other liabilities | |||||||||
3,846 | -1,088 | 2,263 | 4,402 | - | - | - | - | - | - |
Accrued shareholder litigation | |||||||||
900 | - | - | - | - | - | - | - | - | - |
Tax Receivable | |||||||||
- | - | - | - | 10 | 160 | -2,188 | -982 | - | - |
Other assets | |||||||||
- | - | - | - | 95 | - | - | -184 | -211 | -220 |
Accounts payable and accrued expenses | |||||||||
- | - | - | - | - | - | - | - | -3,403 | -1,950 |
Deferred revenue | |||||||||
- | - | - | - | - | -947 | 685 | - | -40,891 | -39,562 |
Accounts payable, accrued expenses, and other current liabilities | |||||||||
- | - | - | - | 2,572 | 2,605 | 665 | -140 | - | - |
Net cash used in operating activities of continuing operations | |||||||||
- | - | - | - | -18,756 | -3,309 | -4,783 | -6,176 | -32,777 | -5,474 |
Loss from operations of discontinued operations, net of income taxes | |||||||||
- | - | - | - | -1,118 | -6,668 | -5,318 | 24,794 | - | - |
Loss from discontinued operations | |||||||||
- | - | - | - | - | - | - | - | - | 38,136 |
Expiration of price protection derivative related to trading securities | |||||||||
- | - | - | - | 1,685 | -1,705 | - | - | - | -44,788 |
Depreciation and amortization | |||||||||
- | - | - | - | - | 156 | 156 | 168 | - | 210 |
Provision for bad debts | |||||||||
- | - | - | - | - | - | - | - | - | 45 |
Non cash share-based payments | |||||||||
- | - | - | - | - | 658 | 598 | 790 | - | 98 |
Accounts receivable and other current assets | |||||||||
- | - | - | - | -15,091 | -113 | 172 | -1,720 | - | - |
Accounts receivable | |||||||||
- | - | - | - | - | - | - | - | - | -1,516 |
Inventory and other current assets | |||||||||
- | - | - | - | - | - | - | - | - | -1,707 |
Accounts payable and accrued expenses | |||||||||
- | - | - | - | -57 | -2,846 | -419 | -772 | -412 | -3,563 |
Deferred revenue | |||||||||
- | - | - | - | - | - | -3,333 | -40,960 | - | - |
Net cash provided by (used in) operations of discontinued operations | |||||||||
- | - | - | - | 15,601 | -10,292 | -8,488 | -14,260 | -412 | -6,639 |
Net cash provided by (used in) operating activities | |||||||||
7,304 | -5,223 | -6,238 | -10,979 | -3,155 | -13,601 | -13,271 | -20,436 | -33,189 | -12,113 |
CASH FLOWS FROM INVESTING ACTIVITIES | |||||||||
Purchases of property and equipment | |||||||||
242 | 2,008 | 1,350 | 927 | 1,123 | 528 | 128 | 81 | 148 | 304 |
Proceeds from sale of investments | |||||||||
16,721 | 32,857 | - | - | - | - | - | - | - | - |
Purchases of certificates of deposit | |||||||||
10,000 | - | - | - | - | - | - | - | - | - |
Purchases of investments | |||||||||
-504 | -25,506 | - | - | - | - | - | - | - | - |
Proceeds from sale of investments | |||||||||
- | - | 14,485 | 120,203 | 114,374 | 55,357 | 217,185 | 284,569 | 33,598 | 54,185 |
Purchases of investments | |||||||||
- | - | 13,133 | 101,384 | 112,192 | 62,640 | 203,733 | 263,984 | 270 | 51,187 |
Proceeds from the sale of property and equipment | |||||||||
- | - | - | - | - | - | - | - | - | 17 |
Proceeds from sale of discontinued operations, net | |||||||||
- | - | - | - | - | 19,751 | - | - | - | 9,736 |
Proceeds from Mesoblast guaranteed payment | |||||||||
- | - | - | 6,180 | - | - | - | - | - | - |
Net cash provided by investing activities | |||||||||
- | - | - | - | 1,059 | 11,940 | 13,324 | 20,504 | 33,180 | - |
Net cash provided by investing activities | |||||||||
5,975 | 5,343 | 2 | 24,072 | - | - | - | - | - | 12,447 |
CASH FLOWS FROM FINANCING ACTIVITIES | |||||||||
Principal payments on capital lease obligations | |||||||||
- | - | - | - | 45 | 44 | 22 | - | 3 | 7 |
Restricted cash | |||||||||
- | - | - | - | 243 | 74 | 75 | 129 | 145 | -536 |
Proceeds from the exercise of options to purchase common stock | |||||||||
- | - | - | - | 1,685 | 2,193 | 87 | 22 | - | - |
Proceeds from the exercise of options to purchase common stock | |||||||||
7 | 128 | 27 | 987 | - | - | - | - | - | - |
Repurchases of common stock | |||||||||
- | - | 32 | 206 | - | - | - | - | - | - |
Payment of dividend | |||||||||
- | - | - | 6,891 | - | - | - | - | - | - |
Other | |||||||||
- | - | 70 | 47 | - | - | - | - | - | - |
Windfall benefit from stock-based compensation | |||||||||
- | - | - | - | 5 | - | - | - | - | - |
Proceeds from the issuance of common stock, net | |||||||||
- | - | - | - | - | - | - | - | 3 | 575 |
Net cash provided by financing activities | |||||||||
- | - | - | - | 1,888 | 2,223 | 140 | 151 | 145 | - |
Net cash provided by financing activities | |||||||||
7 | 128 | -75 | -6,157 | - | - | - | - | - | 32 |
NET INCREASE IN CASH AND CASH EQUIVALENTS | |||||||||
13,286 | 248 | - | - | - | - | - | - | - | - |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | |||||||||
- | - | -6,311 | 6,936 | -208 | 562 | 193 | - | - | 366 |
Net increase (decrease) in cash | |||||||||
- | - | - | - | - | - | - | 219 | 136 | - |
SUPPLEMENTAL INFORMATION | |||||||||
Cash (refunded) paid during the period for: | |||||||||
Income taxes (refunded) | |||||||||
318 | - | - | - | - | - | - | - | - | - |
Income taxes paid | |||||||||
- | 134 | - | - | - | - | - | - | - | - |
Cash paid for interest | |||||||||
- | - | - | - | - | - | - | - | - | 8 |
Income taxes paid, net of refunds | |||||||||
- | - | 93 | 2,453 | 619 | 539 | - | - | 4,281 | 1,257 |
Deferred compensation related to Stryker agreement | |||||||||
- | - | - | - | 5,000 | - | - | - | - | - |
Equipment acquired under a capital lease | |||||||||
- | - | - | - | - | - | 228 | - | - | - |
Guaranteed payment related to trading securities | |||||||||
- | - | - | - | 4,409 | - | - | - | - | - |
Trading securities from the sales of discontinued operations | |||||||||
- | - | - | - | - | 15,000 | - | - | - | - |
Purchase price guarantee related to trading securities | |||||||||
- | - | - | - | - | 1,685 | - | - | - | - |
Proceeds receivable due from sale of discontinued operations | |||||||||
- | - | - | - | - | 15,000 | - | - | - | - |
Unrealized loss on investments available for sale | |||||||||
- | - | - | - | 21 | 13 | 40 | - | - | - |
Transfer of fixed assets from discontinued operations | |||||||||
- | - | - | - | - | - | - | - | - | 3,580 |